In Brief
In this issue, Guillot-Sestier et al. demonstrate that inhibiting IL-10 signaling, a key anti-inflammatory pathway, alters microglial activation in favor of cerebral Ab phagocytosis. These results highlight that rebalancing cerebral innate immunity may be therapeutically relevant for Alzheimer's disease.
INTRODUCTION
Alzheimer's disease (AD), the most common form of dementia in the elderly, is characterized by a triad of pathological features: extracellular amyloid deposits predominantly composed of amyloid-b (Ab) peptides, intracellular neurofibrillary tangles (NFTs) chiefly comprised of abnormally folded tau protein, and gliosis consisting of reactive microglia and astrocytes surrounding b-amyloid plaques. During the past century, intense focus has been directed toward studying production, aggregation, and spreading of b-amyloid plaques and subsequent neurodegeneration (Mucke and Selkoe, 2012) . These studies have led to the conclusion that AD pathology is driven by an imbalance between Ab production and clearance.
Indeed, autosomal-dominant forms of familial Alzheimer's disease (FAD) are principally linked to mutations affecting b-amyloid precursor protein (b-APP) or Presenilin 1 (PS1) function (De Strooper et al., 2012) , leading to amyloidogenic processing of b-APP and accumulation of cerebral amyloid deposits. Nonetheless, the vast majority of patients have the sporadic form of the disease, which likely arises from a combination of poorly defined genetic and environmental risk factors. These factors do not necessarily affect b-APP proteolysis, and it has instead been suggested that dysregulated Ab clearance-rather than production-is the etiologic driving force in sporadic AD (Mawuenyega et al., 2010) . As the resident macrophages of the CNS, microglia are chiefly responsible for phagocytosis and clearance of cellular detritus. Furthermore, numerous studies have validated the ability of microglia to phagocytose Ab peptides (Grathwohl et al., 2009; Herber et al., 2004; Wilcock et al., 2004; Wyss-Coray et al., 2001 ). However, mounting evidence suggests that microglia are dysfunctional in the AD brain (Lopes et al., 2008; Streit et al., 2009) . While prolonged activation of brain inflammatory processes coordinated by the cerebral innate immune system is now accepted as an AD etiologic event (Wyss-Coray and Mucke, 2002) , the role of anti-inflammatory pathways in Ab clearance and AD pathobiology has been largely overlooked.
Inflammatory responses are kept under control by two key immunoregulatory cytokines: transforming growth factor-b (TGF-b) and interleukin-10 (IL-10) (Li and Flavell, 2008; Strle et al., 2001; Williams et al., 2004; Wyss-Coray and Mucke, 2002) . Our laboratory has previously shown that blockade of anti-inflammatory TGF-b-Smad 2/3 signaling in innate immune cells mitigates cerebral amyloidosis and behavioral deficits in the Tg2576 mouse model (Town et al., 2008) . These data suggest that the innate immune system can be harnessed to clear Ab in the context of anti-inflammatory signaling inhibition. Remarkably, cerebral levels of IL-10 were increased in this scenario, in line with the elevated IL-10 signaling observed in reactive glia neighboring b-amyloid plaques in aged Tg2576 mice (Apelt and Schliebs, 2001 ). Also, a functional polymorphism within the Il10 gene has been linked to increased risk of AD in some (Arosio et al., 2004; Lio et al., 2003; Ma et al., 2005; Vural et al., 2009 ), but not all, populations (Depboylu et al., 2003; Ramos et al., 2006; Scassellati et al., 2004) .
IL-10 signaling induced by binding of IL-10 homodimer to its cognate receptor (IL-10R) leads to phosphorylation of associated Janus kinase 1 (Jak1) and downstream phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3). Phosphorylated STAT3 translocates to the nucleus, where it regulates transcription of downstream cytokines and inflammatory genes including SOCS3 (Murray, 2006) . To investigate putative involvement of the IL-10 pathway in AD-like pathology, we crossed the Tg(APP swe , PS1 DE9 ) mouse model of cerebral amyloidosis with animals deficient in Il10. Genetic disruption of Il10 licensed Ab phagocytosis by activated microglia and reduced Ab load in APP/PS1 mouse brains. Transcriptome analysis of brains from APP/PS1
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À/À mice by RNA sequencing (RNAseq) revealed modulation of the inflammatory milieu, including select inflammatory and microglial regulatory genes. Finally, Il10 deficiency partially rescued synaptic toxicity and behavioral impairment driven by the APP/PS1 transgenes.
RESULTS
Deficiency in Il10
Mitigates Cerebral Amyloidosis in APP/PS1 Mice To assess the role of Il10 in AD-like pathology, we bred Il10 Kü hn et al., 1993) to Tg(APP swe ,PSEN1 DE9 ) animals (referred as APP/PS1 mice in the present study) (Jankowsky et al., 2001 (Jankowsky et al., , 2004 Figure 1C ; CC, 67%; EC, 50%; HC, 70%, *p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA and Dunnett's post hoc test). Ab plaque morphometry was analyzed by blindly assigning plaques to one of three mutually exclusive categories based on maximum diameter. Surprisingly, APP/PS1
mice had modest but statistically significant increases in abundance of small (<25 mm) plaques in the CC and EC versus APP/ PS1 + Il10 +/+ animals (Figure S1A, *p < 0.05 by one-way ANOVA and Fisher's post hoc test). Yet, numbers of medium-(25-50 mm) and large-sized (>50 mm) plaques were significantly reduced by 48%-74% in the CC, and this effect trended toward significance in the EC and HC (Figures S1B and S1C, *p < 0.05; by one-way ANOVA and Fisher's post hoc test). In addition to Ab plaques in brain parenchyma, 86% of AD patients deposit Ab in cerebral blood vessels, known as cerebral amyloid angiopathy (CAA) (Ellis et al., 1996; Kanekiyo et al., 2012 To rule out the possibility of an effect on cerebral amyloidosis due to altered APP Swe or PS1 DE9 transgene expression, western blot and quantitative real-time reverse transcriptase PCR (qPCR) analyses were performed on protein and RNA extracted from frontal cortex of all three groups of mice. No between-groups differences were found on PS1 or APP protein or mRNA levels ( Figures 1I-1K ). To determine if Il10 deficiency altered APP metabolism, amyloidogenic C99 fragments were detected in frontal cortex brain extracts (n = 5 to 6 for each mouse group) by western blot but remained unmodified (quantitation of C99 band intensity normalized to holo-APP and b-actin: APP/PS1 + Il10 Il10 Deficiency Activates Innate Immunity in Brains of APP/PS1 Mice Within the CNS, IL-10 is mainly produced by astrocytes and microglia (Ledeboer et al., 2002) , the latter being brain-resident innate immune cells that are centrally positioned to phagocytose and clear Ab (Aguzzi et al., 2013; Guillot-Sestier and Town, 2013) . To confirm the cellular source of cerebral IL-10 in our experimental animals, Il10 mRNA levels were analyzed by qPCR in CD11b + and CD11b À cellular fractions isolated from brain single-cell suspensions ( Figure S2A ). The CD11b + cell fraction highly expressed established microglial markers (i.e., Iba1, Cx3cr1, Csf1r, and Itgb5; Figure S2A ) (Butovsky et al., 2014) , while the CD11b À cell fraction expressed astrocytic and neuronal markers (i.e., S100b and Map2). Interestingly, the CD11b + fraction was largely enriched in Il10r mRNA compared to CD11b
À cells, and Il10r expression was strikingly increased in microglia from APP/PS1 + animals ( Figure S2A ). Finally, Il10 mRNA levels were markedly increased in microglia from APP/ greater than 2-fold differences. Cluster analysis of those 117 genes was performed, resulting in three distinct patterns: A, B, and C ( Figure 3B ). We further defined these groups as A1, A2, B, and C, where group A1 and A2 genes were decreased in APP/PS1 + Il10 À/À mice and APP/PS1 + Il10 +/À mice had an intermediate result; group B genes were only decreased in APP/ PS1 + Il10 À/À mice, and group C genes were increased in APP/ PS1 + Il10 À/À mice. When these genes were further interrogated for immune-related function(s), the majority of immune genes fell into groups A1 and A2 ( Figure 3B ). These genes, corresponding fold changes with associated statistical significance levels, and global function(s) in immune responses are presented in Figure 3C . Interestingly, expression of Apoe (a wellestablished genetic risk factor for late-onset AD) was reduced
dating microglial qPCR data (see Figure S2A ). In general, immune genes with altered expression profiles were responsible for innate immune cell regulation, chemoattraction, Ab interaction, and phagocytosis. 
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+/+ signal normalized to 100%; non-significant.
(K) qPCR analysis of APP and PS1 mRNA levels in frontal cortex from mice with the indicated genotypes. The mRNA levels are normalized to Hprt, and data are represented as mean ± SEM for n = 6 per group; non-significant. See also Figure S1 .
post hoc test). To determine if Stat3 knockdown could phenocopy the effect of Il10 deletion on microglial Ab phagocytosis, we used a mouse microglial cell line (N9) that responded similarly to mouse primary microglia in terms of IL-10-dependent reduction of Ab phagocytosis ( Figure S4F , *p < 0.05; by t test). Three independent Stat3 knockdown microglial N9 lines were generated via shStat3 lentiviral infection, and STAT3 expression was (Figure 3 ) and microglial qPCR ( Figure S2A) Figure 4H ). This was confirmed by ELISA quantitation of Ab uptake in a parallel set of experiments using unlabeled Ab ( Figure 4I , **p < 0.01, ***p < 0.001; by one-way ANOVA and post hoc t test Figures 5A-5C ). Western blot analysis of cortical protein extracts confirmed our immunohistochemical observations ( Figure 5D ), and densitometric analysis disclosed were cognitively evaluated. Prior to behavioral testing, mice were subjected to neurological screening to assess auditory, visual, and olfactory acuity and response to a tactile stimulus. Additionally, coordination, balance, and grip strength were tested. Mice performed equally well for each of the neurological screening tests (data not shown), and so all animals were included in subsequent behavioral assays. Locomotion and spontaneous activity were tested in an open field. Yet, no significant differences between any of the six groups were observed when considering rearing or time spent in the center of the field ( Figure S5A ), indicating that subsequent behavioral results were not distorted by variation in anxiety between genotypes. However, when considering fine movements (i.e., grooming, exploration on four limbs, and sniffing) and total activity, APP/ PS1 + Il10 +/+ mice were hyperactive versus controls, a behavioral phenotype that may result from cortical and hippocampal injury leading to disinhibition (Town et al., 2008) . Strikingly, APP/PS1
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À/À mice had complete mitigation of hyperactivity (Figures 6A and S5A; y p < 0.1, *p < 0.05, ****p < 0.0001; by one-way ANOVA and Fisher's LSD post hoc test). Next, learning and episodic memory were assessed in the novel object recognition test, which is dependent on hippocampal and cortical function (Hammond et al., 2004) . If mice remember a previously encountered object compared to a novel object, they tend to preferentially explore the new object more than the familiar one. As expected, after a 1 hr retention period, APP/PS1 + Il10 +/+ mice trended toward lower preference for the novel object than controls ( Figure 6B ; y p = 0.07; by one-way ANOVA and Fisher's LSD post hoc test). Strikingly, defective novel object recognition was completely remediated by Il10 deficiency, and partial amelioration of this behavioral defect was observed in APP/PS1 + Il10 +/À mice ( Figure 6B) . A similar trend of results occurred after 24 hr of retention ( Figure S5B ). Importantly, neither short-term (1 hr) nor long-term (24 hr) novel object memory were affected by Il10 deficiency in nontransgenic controls ( Figure 6B and Figure S5B ; p > 0.05, by one-way ANOVA and Fisher's LSD or Sidak's post hoc tests, respectively). Spatial working memory was evaluated by spontaneous alternation in the Y-maze (Deacon et al., 2002 
+/+ mouse percentage spontaneous alternation trended toward less frequent than controls, and Il10 deficiency did not modify this effect ( Figure 6D , y p = 0.07; by one-way ANOVA and Fisher's LSD post hoc test). As an important control, deficiency in Il10 did not alter spontaneous alternation in control littermates lacking the APP/PS1 transgene ( Figure 6D, Figure S5D , *p < 0.05; by one-way ANOVA and Fisher's LSD post hoc test). During the reversal phase of the test, no differences in acquisition of the new escape box location were observed between the six groups ( Figure S5E , p < 0.05; by one-way ANOVA and Fisher's LSD post hoc test). No statistically significant gender differences were found for any of the behavioral paradigms, and so males and females were considered together in all behavioral analyses.
IL-10 Signaling Is Elevated in AD Patient Brains
Finally, we sought to evaluate IL-10 signaling in postmortem samples from AD patient brains versus age-matched, nondemented controls. Hippocampal sections were stained for IL-10 receptor alpha chain (IL-10Ra) and microtubule-associated protein 2 (MAP2, a neuronal marker). Interestingly, IL10Ra expression was elevated in AD compared to control brains, and some of these signals could be found colocalized with ). Cells were treated for 6 hr with human synthetic Ab 1-42 preaggregated in presence of recombinant ApoE2, ApoE3, or ApoE4. Data are presented as mean ± SEM of two independent experiments carried out in duplicate; **p < 0.01; ***p < 0.001. See also Figure S4 and Movies S1 and S2. **p < 0.01; by student's t test). Furthermore, phospho-Jak1, a key downstream effector kinase of the IL-10 pathway, was elevated in AD brains in close proximity to thioflavin S + amyloid plaques ( Figures 7C and 7D , *p < 0.05; by student's t test). Western blot analyses of hippocampal protein extracts from a separate cohort confirmed our immunohistochemical observations, with densitometry disclosing increases of 6.5-fold in IL10Ra (Figure 7E , *p < 0.05), 2.3-fold in Jak1 ( Figure 7F , yp = 0.09), 2.6-fold in phospho-Jak1 ( Figure 7G , *p < 0.05), 4.2-fold in STAT3 (Figure 7H , *p < 0.05), 1.6-fold in phospho-STAT3 ( Figure 7I , yp = 0.1), and 1.9-fold in SOCS3 ( Figure 7J , yp = 0.07) abundance (all by student's t test). Taken together, these data indicate elevated IL-10 signaling in AD patient versus age-matched control brains. Interestingly, we also observed increased Il10 and Il10r mRNA levels in microglia isolated from brains of APP/ PS1 + mice ( Figure S2A ).
DISCUSSION
While once regarded as epiphenomenon, the impact of the cerebral innate immune response on AD pathology has become a topic of intense interest (Gandy and Heppner, 2013; Guillot-Sestier and Town, 2013; Weitz and Town, 2012) . This has prompted the need for a deeper understanding of which innate immune pathways are deregulated in the context of the disease. While proinflammatory cytokines have received attention in this regard, the concept that dysregulated anti-inflammatory cytokines may be deleterious in AD has been largely overlooked. While several studies have shown that Il10 polymorphism is associated with late onset AD (Arosio et al., 2004; Lio et al., 2003; Ma et al., 2005; Vural et al., 2009) , almost nothing is known regarding the putative role of IL-10 in evolution of disease pathology. To address this knowledge gap, we generated APP/PS1 mice deficient for Il10 and evaluated AD-like pathology and cognitive impairment. Results showed strikingly reduced cerebral amyloid pathology in these animals, and remaining plaques were associated with activated microglia. Interestingly, plaques in APP/ PS1 + Il10 À/À mice had a ''moth-eaten'' morphology, similar to observations made in brains of AD patients or APP transgenic mice after Ab 1-42 immunization (Bard et al., 2000; Nicoll et al., 2003 Nicoll et al., , 2006 Schenk et al., 1999; Zotova et al., 2011) . Importantly, CD68 + phagocytic microglial cells were observed invading moth-eaten plaques in APP/PS1 + Il10 À/À brains. Recently, Krabbe and colleagues showed that microglial cells fail to reduce Ab burden in transgenic mouse models of AD due to impaired mobility and phagocytic capacity (Krabbe et al., 2013) . Microglial ''paralysis'' may be owed to increasing Ab burden with disease progression, as shown by others in vitro and in vivo (Korotzer et al., 1993; Krabbe et al., 2013; Michelucci et al., 2009 ). Alternatively, it has been hypothesized that microglial senescence in the aging brain could be responsible for reduced capacity of these cells to clear cerebral amyloid (Lopes et al., 2008; Miller and Streit, 2007; Streit et al., 2009 ). The results we report here show that stimulation of microglia by recombinant IL-10 induces nuclear translocation of the downstream signal transducer STAT3 and reduces Ab phagocytosis, whereas Il10 deficiency or Stat3 knockdown increases Ab uptake by cultured microglia. Additionally, Il10 deficiency increases microglial activation and promotes Ab uptake into Lamp1 + and CD68 + phagolysosomes in vivo. In this regard, Il10 deficiency in APP/PS1 mice seems to restore physiologic ability to phagocytose Ab. These findings dovetail with previous studies from our laboratory and others, showing that induction of a proinflammatory activation state endorses cerebral amyloid clearance (Chakrabarty et al., 2010a (Chakrabarty et al., , 2010b (Chakrabarty et al., , 2011 Shaftel et al., 2007; Town et al., 2008) . We did not observe histological evidence of brain-infiltrating peripheral mononuclear phagocytes in APP/PS1 + Il10 À/À mice (i.e., vascular cuffing or presence of round, non-process-bearing leukocytes) as we previously reported in a different innate immune paradigm (Town et al., 2008 brains, suggesting that brain-resident microglia are likely the major population responsible for amyloid clearance. However, direct experiments aimed at firmly delineating the role of peripheral versus central phagocytes in clearance of Ab are warranted. The study of global transcriptome changes in brains of APP/ PS1 mice via RNAseq demonstrates that Il10 deficiency modifies cerebral innate immunity. During the analysis, we considered classical markers for M2-like (TGF-b, Ym-1, and Fizz) and M1-like (TNF-a, IL-1b, and IL-6) innate immune activation states. However, we did not detect differential expression of these targets. Yet, Clec7a expression was strongly decreased in APP/ PS1 + Il10 À/À mice, suggesting polarization of microglial activation away from the M2 state. Depending on the type of stimulation, microglia demonstrate remarkable plasticity and often respond with a mixed activation phenotype (Ghassabeh et al., 2006; ; therefore, we have previously suggested that M1 or M2 define boundaries of a more broad microglial activation continuum . Nonetheless, our data reveal global changes in genes that regulate innate immune activation, inflammation, and phagocytosis. Interestingly, genes upregulated in brains of patients with late onset AD such as Tyrobp, Trem2, and C4b (Brouwers et al., 2012; McGeer et al., 1989; Zhang et al., 2013) were decreased in brains of Il10-deficient APP/PS1 mice. Along similar lines, previous studies have shown that TLR2 and C4b bind Ab and trigger microglial activation (Richard et al., 2008) and Ab fibril formation (Sjö lander et al., 2012; Trouw et al., 2008) , and APP/PS1 + Il10 À/À brains had decreased expression of both genes. Strikingly, Chakrabarty and coworkers have demonstrated that adeno-associated viral expression of Il10 in brains of APP transgenic mice leads to age-dependent upregulation of Cxcl10, Tlr2, C4b, and C3ar1 transcripts (Chakrabarty et al., 2015) . These global gene expression results corroborate our data showing that Il10 deficiency restores microglial functionality that is compromised in APP/PS1 transgenic mice. Of particular interest, Apoe expression was reduced in APP/PS1 + Il10 À/À mice as shown by brain RNAseq (log 2 FC = À0.6, FDR = 4 3 10 À5 ) and by microglial qPCR. In vitro, recombinant human ApoE3 and ApoE4 drastically impaired Ab uptake by microglia, while ApoE2 had no effect, mirroring the well-established ApoE-human AD risk relationship. Strikingly, Il10 deficiency partially rescued human ApoE3-associated reduction of Ab uptake compared to Il10 +/+ microglia, but was unable to recover the deleterious effect of human ApoE4. Again, this tracks well with ApoE4 increased risk for human AD. 
But does remodeling of cerebral amyloid in APP/PS1
+ Il10 À/À mice come at the cost of bystander injury to neurons? This question is especially pertinent because we and others have shown that gliosis can potentially be toxic to neurons in the context of AD (Maezawa et al., 2011; Meda et al., 1995; Tan et al., 1999) . Given changes in immune gene expression profile associated with Il10 deficiency and mitigation of cerebral amyloid load, we examined synaptic health in APP/PS1 + Il10 À/À animals. Synaptophysin density was reduced in HC and cortex of APP/PS1 mice compared to non-transgenic controls, as reported in transgenic mouse models of cerebral amyloidosis and in AD patients (Buttini et al., 2005; Imbimbo et al., 2010; Tampellini et al., 2010; Ubhi et al., 2010) . Interestingly, synaptophysin loss in APP/PS1 mice was almost completely restored by Il10 deficiency, indicating that innate immune activation associated with amyloid clearance in APP/PS1
+
Il10
À/À mice preserved synaptic integrity.
Behavioral analyses were performed to determine whether maintenance of synaptic health in APP/PS1 + Il10 À/À mice translated to better cognitive function. Importantly, in non-transgenic control groups, Il10 deficiency did not alter anxiety, learning, or memory. On the other hand, APP/PS1 mice were hyperactive, likely resulting from disinhibition associated with hippocampal or cortical damage (Hsiao et al., 1996; Town et al., 2008) . Additionally, novel object recognition and spatial working memory were defective in APP/PS1 mice, as previously reported (Hooijmans et al., 2009; O'Leary and Brown, 2009; Webster et al., 2013 To address the possibility that we were simply studying iatrogenic events not related to human AD, we investigated IL-10 signaling in AD patients versus cognitively healthy, age-matched controls. Data showed that expression of the cognate IL-10 receptor, IL10Ra, was elevated in AD patient brains compared to age-matched, non-demented individuals. Phosphorylated (activated) Jak1 was correspondingly increased in cells surrounding amyloid plaques in AD specimens, and protein levels of IL-10 receptor and downstream effectors were elevated in AD hippocampal homogenates. Collectively, these results indicate abnormally increased IL-10 signaling in AD patient brains. These results corroborate and extend the observations of other groups that reported increased levels of IL-10 in serum and brain extracts from AD patients (Angelopoulos et al., 2008; Culpan et al., 2006; Loewenbrueck et al., 2010) . Furthermore, we noted that Il10 as well as IL10r mRNA levels were increased in microglia extracted from APP/PS1
+
Il10
+/+ mouse brains, suggesting an autocrine signaling mechanism associated with increased cerebral amyloidosis, a finding that is in line with the IL-10 immunoreactive cells observed in close vicinity to b-amyloid deposits in 13-month-old Tg2576 mice (Apelt and Schliebs, 2001 ). Since we show that recombinant IL-10 treatment inhibits Ab uptake by cultured microglia, elevated IL-10 signaling in AD patient brains and APP/PS1 + mice may hinder the physiological ability of microglia to phagocytose and clear cerebral amyloid.
Altogether, our findings show that genetic blockade of Il10 promotes a beneficial form of cerebral innate immunity. Il10 blockade enables cerebral Ab clearance via two independent mechanisms: (1) reducing IL-10/STAT3 signaling to enhance microglial phagocytic activity and (2) decreasing microglial Apoe expression, thereby mitigating ApoE-Ab binding and detrimental reduction of Ab phagocytosis. Importantly, our data are consistent with recent results showing that forced Il10 expression in brains of APP transgenic mice leads to increased Ab accumulation and worsening of behavioral deficits (Chakrabarty et al., 2015) . Therefore, modulating IL-10 signaling alters the microglial activation footprint and Ab phagocytosis. Collectively, these results suggest that rebalancing cerebral innate immunity and promoting beneficial neuroinflammation may be more efficacious than generalized anti-inflammatory therapy for AD.
EXPERIMENTAL PROCEDURES
Please see Supplemental Experimental Procedures for detailed methods on immunochemistry, primary microglia isolation, flow cytometry, cell culture, transfection and viral infection, live cell imaging, Ab uptake quantitation, western blots, ELISA and MSD technology, RNAseq and qPCR, and behavioral experiments.
Human Brain Samples
Frozen human brain tissue used for western blotting was obtained from the Alzheimer's Disease Research Center (ADRC, NIA AG05142) Neuropathology Core (three female and five male AD patient hippocampal samples, 51-100 years old, and four female and two male control hippocampal samples, 74-93 years old). For IHC, paraffin-embedded 10-mm-thick sections from the HC of six AD patients (three females and three males, 84-87 years old) and three age-matched non-demented control subjects were obtained from Dr. Serguei Bannykh, director of the Department of Neuropathology at Cedars-Sinai Medical Center. 
Tissue Handling
Mice were perfused with ice-cold PBS and brains were extracted and quartered according to our previously published methods (Tan et al., 2002; Town et al., 2008) . The anterior two quarters were snap-frozen and posterior quarters were fixed in 4% paraformaldehyde overnight for subsequent agarose or paraffin embedding.
3D Reconstruction of Confocal Images
Confocal image stacks (acquired at 603 magnification) of amyloid depositsassociated microglia were converted to 3D images with the surface-rendering feature of Imaris BitPlane software (version 7.6.1).
RNAseq Gene Expression Analysis
Strand-specific libraries were generated with 1 mg of input RNA using the TruSeq Stranded mRNA Sample Prep Kit (Illumina) on an Illumnia HiSeq 2000. Gene classes were generated with Cluster3 by applying k means clustering to mean-centered log 2 (RPKM) expression values (de Hoon et al., 2004) . Classification of a gene as immune-related was based on KEGG pathway annotation (www.genome.jp/kegg).
Behavioral Analyses
Behavioral experiments were conducted with age-matched littermates from 12 to 13 months of age, inclusive of the following six genotypes: Il10 . All experiments were done blind with respect to the genotype of the mice. After neurological screening, behavioral tests were conducted in increasing order of difficulty and stress ranging from open field testing, novel object recognition, the Y-maze task, and the Barnes maze. For each test independently, mice that did not perform the exercise were excluded from the analysis.
Statistical Analysis
GraphPad Prism software, version 6.0, was used for all statistics. Multiple group comparisons were performed by one-way analysis of variance followed by Dunnett's, Sidak's, or Fisher's LSD post hoc tests. Otherwise, Student's t test was performed. For each behavioral test, possible gender differences within each group were statistically evaluated by analysis of variance, followed by Sidak's multiple comparison test. In all cases, p % 0.05 was considered to be statistically significant. All data are presented as means ± SEM.
ACCESSION NUMBERS
The RNAseq data have been deposited under NCBI BioProject accession number PRJNA219136. 
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